Thyroid RFA 101: The Future is Very Bright for Treating Benign Nodules and Primary Low Risk Thyroid Cancers
American Thyroid Association National Meeting
October 17-22 2017
1500 of the world expert thyroidologists and over
500 of the clinical endocrinologists met in Victoria BC.
My original objective was to make a presentation on the
Use of ablation procedures to treat thyroid disease. To
highlight the new safety methods and devices developed by
Dr.Baek in my presentation. To demonstrate some of
these used in my Master’s class in Thyroid RFA and PEI.
To recruit The clinical endocrinologists who do their own biopsies to Consider learning Thyroid RFA. To inform them about AACE’s formation of a thyroid RFA task force ( I am a member) to begin to develop a Training program in certification.To inform the clinical endocrinologists about the thyroidablation.net website begun in Boston 2017 at the World Thyroid Cancer Congress for thyroid ablation.
The meeting was a success and our exhibit booth was well
designed to promote Thyroid RFA. A number of endocrinologists And others attending knew about Thyroid RFA from my website and thyroid blog. The current trend in
thyroid is to develop molecular markers to be able to
Tell if a thyroid nodule is cancer, and if that cancer has the
Potential to cause serious complications or death. Every expert in the field stated that marker testing will be able To tell which nodules and cancer are safe to ablate in plac
And not need surgery. Dr.Syd Finkelstein of Interpace and Dr.Yuri Nikiforov from U of Pittsburgh both leading marker experts told be while visiting my booth take thyroid RFA will become more and more Important to treat these low risk cancers without surgery. Also, Dr.Ian Hay from the Mayo Clinic, a pioneer in ablation methods is already ablating small primary micro-papillary Cancers with ethanol. Thyroid RFA is a better fit to treat As shown by Dr.Baek. Thyroid ablation is the third arm tom surgery and active surveillance for low risk cancers.
We were the only exhibit booth about thyroid RFA. We had
one of several Papers on thyroidRFA. Medtronic was there
but had nothing on microwave. We recruited 6 clinical
endocrinologists for my Thyroid RFA private master’s class to learn Thyroid RFA. They do 300-500
FNAs a year and can be part of the clinical trials on the
thyroid nodules to start after training and FDA approval.
The exciting finding was the potential of microRNA to
Tell which nodules can be ablated even if they are cancers
That are low risk.Also the present use of Active Surveillance
Vs surgery of low risk primary cancers has a new option of
Thyroid RFA Ablation and ethanol ablation ( Ian Hay at
The objectives set forward when I proposed a booth and
paper at this meeting was met and exceeded. We now know
ThyroidRFA will be the dominate method to treat benign and
low risk cancers in the next 5 years, and replace surgery
for my happy thyroid patients.
Richard Guttler MD,FACE,ECNU